In short
Clinical trials are investigating VTX-002 in people with amyotrophic lateral sclerosis (ALS). This article explains what the study is trying to learn, who may take part, and which safety measures and outcomes are being checked. The main focus is safety and tolerability in a small Phase 1/2 study.
Key points
- Clinical trials are studying VTX-002 in people with amyotrophic lateral sclerosis (ALS). The available trial is a Phase 1/2 interventional study with 12 planned participants and is listed as Authorised. Its main goal is to assess the safety and tolerability of a single administration of increasing doses of VTX-002. The study also measures adverse events, laboratory values, MRI findings, nerve symptom scores, cellular responses, and suicide severity ratings. Overall, the trial is focused on early safety data in a small ALS group.
Trial overview
The available study of VTX-002 is titled “A Phase 1/2 Study of the Safety and Tolerability of ICM VTx-002 in participants with ALS.” It is an interventional trial, which means researchers give the study treatment and then watch what happens. The trial is listed as Authorised and plans to enroll 12 participants.
Who is being studied
This trial is for people with amyotrophic lateral sclerosis (ALS). ALS is the condition named in the trial record, and no other target population is listed. The source data do not provide more detailed inclusion or exclusion rules, so the exact entry criteria are not known from the trial summary alone.
What the study measures
The main goal is to assess the safety and tolerability of increasing doses of a single administration of VTX-002. Safety means whether unwanted medical problems happen, and tolerability means how well participants can handle the treatment.
The primary outcome looks at the nature, number, severity, relatedness, seriousness, and outcome of treatment-emergent adverse events (new health problems that start after treatment begins). The study also checks laboratory values, MRI findings, the Treatment-induced Peripheral Neuropathy Assessment Scale (TNAS), cellular responses to both the vector and the transgene encoded protein, and the Columbia Suicide Severity Rating Scale (C-SSRS).
These measures help researchers see whether the treatment affects the body in ways that may matter for future research in ALS. They also give a fuller safety picture than side effects alone because they include scans, blood or other test results, nerve symptom checks, and mental health screening.
Trial design and phase
This study is in Phase 1/2, which is an early stage of clinical research. Early-phase studies usually focus on safety first, and they may also begin to look for other signals that help plan later trials.
The brief summary says the study is designed to assess increasing doses of a single administration of VTX-002. The trial data also list VTx-002 Diluent as an intervention, but the main study focus remains VTX-002 in participants with ALS.
Why this trial matters
ALS is a serious disease, so early studies like this are important for learning whether a new treatment can be studied safely in this group. Because the trial is small and focused on safety, it is not designed to answer all questions about benefit. Instead, it provides early information that can help decide whether larger studies should be done later.